Zai Lab Limited reports developments for a commercial-stage biopharmaceutical company with American depositary shares traded under ZLAB and ordinary shares listed in Hong Kong. The company discovers, develops, licenses and commercializes therapies for oncology, immunology, neuroscience and infectious disease, with operations based in China and the United States.
Recurring company updates include financial results, regulatory designations, clinical and preclinical data, collaborations and product updates across programs such as zocilurtatug pelitecan, ZL-1503, ZL-6201 and ZL-1222. Updates also address regional commercial products and pipeline assets including ZEJULA, VYVGART, KarXT and TIVDAK.
Zai Lab (ZLAB) will present its first clinical trial data for ZL-1503 at the ACAAI meeting on November 13, 2026. The presentation covers healthy volunteers in the Phase 1/1b trial of the internally developed antibody, which targets IL-13 and IL-31 receptor signaling in atopic diseases.
The findings will include single-dose pharmacokinetic data, describing how the drug moves through the body, and pharmacodynamic data, describing its effects on disease-related biomarkers across different doses. Initial safety data and immune responses to the antibody will also be presented. The poster is scheduled for 2:50 p.m. Mountain Time in Phoenix. Zai Lab will hold an investor call and webcast that day at 8:00 a.m. ET to discuss the presented data and clinical trial plans.
Zai Lab (ZLAB) will present first global zoci trial data for first-line extensive-stage small cell lung cancer at ESMO on October 26, 2026. The Phase 1b/1c trial cohort is evaluating zoci with atezolizumab, with or without carboplatin. Zai Lab has scheduled an investor call to discuss the data and its zoci clinical trial plans on October 23.
argenx (NASDAQ: ARGX) and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) reported positive topline results from the global Phase 3 ALKIVIA trial of subcutaneous efgartigimod (VYVGART Hytrulo) in adults with autoimmune myositis. The study met its primary endpoint, showing a 15.4‑point greater mean Total Improvement Score (TIS) at Week 52 versus placebo in the combined IMNM and DM population (47.95 vs 32.56; p=0.0011).
Prespecified analyses showed a 14.8‑point TIS benefit in IMNM (45.05 vs 30.24; p=0.0048) and a similar 14.5‑point improvement in DM (51.51 vs 36.96; p=0.1093). Improvements emerged by Week 4, were sustained through one year with corticosteroid tapering, and all six TIS core measures favored efgartigimod. The safety profile was well‑tolerated and consistent with prior efgartigimod studies. argenx holds exclusive Greater China rights with Zai Lab, which recruited Chinese patients.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) reported second quarter 2026 total revenue of $106.3 million, down from $110.0 million a year earlier. Net product revenue was $105.8 million, with an 11% sequential increase versus the prior quarter driven by stabilization of ZEJULA and volume growth for VYVGART.
R&D expenses rose to $61.8 million and SG&A expenses were $72.9 million. Loss from operations was $76.5 million (or $60.4 million on a non-GAAP basis), and net loss was $50.8 million. Cash, cash equivalents, short-term investments, and current restricted cash totaled $717.5 million at June 30, 2026.
The company highlighted progress across its pipeline, including multiple regulatory designations for zocilurtatug pelitecan (zoci), NMPA approval of TIVDAK in China, advancement of ZL-1503 Phase 1/1b, the commercial launch of KarXT in mainland China for schizophrenia, and participation in several global late-stage programs with partners.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to its DLL3‑targeting antibody-drug conjugate zocilurtatug pelitecan (zoci, formerly ZL‑1310) for the treatment of neuroendocrine carcinomas (NECs), aggressive malignancies with no approved targeted therapies or standard of care for previously treated patients.
According to Zai Lab, zoci previously received FDA Fast Track designation for extrapulmonary NECs and both Fast Track and ODD for small cell lung cancer, while the European Medicines Agency granted ODD for pulmonary NECs. ODD may provide U.S. development incentives, including certain fee waivers, tax credits, and potential seven-year market exclusivity upon approval. Zai Lab plans three registration-enabling studies in SCLC and extrapulmonary NECs by the end of 2026, positioning zoci as a potential first global oncology launch for the company.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before U.S. market open. The company will host a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT) the same day.
Investors can access the live webcast via Zai Lab’s investor relations website, with separate online registration links provided for webcast and dial-in access. A replay will be available on the company’s website shortly after the event.
Zai Lab (NASDAQ:ZLAB) announced that the European Medicines Agency granted Orphan Drug Designation to zocilurtatug pelitecan (zoci) for treating pulmonary neuroendocrine carcinomas (NECs).
The EMA’s committee cited preliminary data in relapsed/refractory extensive-stage small cell lung cancer suggesting a clinically relevant advantage over current therapies and durable responses.
The designation offers potential market exclusivity, reduced fees, and development incentives.
Zai Lab (NASDAQ:ZLAB) received China NMPA approval for TIVDAK (tisotumab vedotin) to treat adult patients with recurrent or metastatic cervical cancer progressing on or after chemotherapy.
The approval is based on Phase 3 innovaTV 301 data showing overall survival benefit versus chemotherapy, including a consistent benefit in the China subpopulation.
Zai Lab (NASDAQ:ZLAB) announced senior leadership changes to support operational performance and efficiency. The Board decided that President and COO Josh Smiley will leave the company, effective Friday, May 22.
Zai Lab expects multiple clinical data readouts in 2026 for lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary NECs, and ZL-1503 from a global Phase 1/1b study. The company is also preparing for the launch of COBENFY™ in China and for multiple anticipated regional regulatory approvals and data readouts.
Zai Lab (NASDAQ:ZLAB) received U.S. FDA Fast Track Designation for zocilurtatug pelitecan (zoci), a DLL3-targeting ADC, to treat extrapulmonary neuroendocrine carcinomas (epNECs) after progression on first-line therapy.
Zoci showed a 38.2% ORR and a manageable safety profile in an ongoing Phase 1b/2 trial and already holds Fast Track for ES-SCLC.